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Abstract
Background and Aims: To improve management of patients with Crohn’s disease, objective 
measurements of disease activity are needed. Ileocolonoscopy is the current reference standard 
but has limitations that restrict repeated use. Ultrasonography is potentially useful for activity 
monitoring, but no validated sonographic activity index is currently in widespread use. Thus, we 
aimed to construct and validate a simple ultrasound score for Crohn’s disease.
Methods: Forty patients were prospectively examined with ultrasound and endoscopy in the 
development phase. The Simple Endoscopic Score for Crohn’s Disease [SES-CD] was used as a 
reference standard. Seven ultrasound variables [bowel wall thickness, length, colour Doppler, 
stenosis, fistula, stratification and fatty wrapping] were initially included, and multiple linear 
regression was used to select the variables that should be included in the final score. Second, the 
ultrasound data from each patient were re-examined for interobserver assessment using weighted 
kappa and intraclass correlation. Finally, the activity index was validated in a new cohort of 124 
patients.
Results: Length, fistula and stenosis were excluded. The combination of the remaining variables 
provided a multiple correlation coefficient of r = 0.78. Interobserver analysis revealed poor 
agreement for stratification and fatty wrapping and these were thus excluded. There was excellent 
interobserver agreement for the remaining score consisting of wall thickness and colour Doppler. 
In both patient cohorts, the ultrasound score correlated well with SES-CD [Development cohort: 
rho = 0.83, p < 0.001, Validation cohort: rho = 0.78, p < 0.001]. A  receiver operating characteristic 
curve analysis revealed an area under the curve of 0.92 and 0.88 for detecting endoscopic activity 
and moderate endoscopic activity, respectively.
Conclusions: A simple ultrasound activity index for Crohn’s disease consisting of bowel wall 
thickness and colour Doppler was constructed and validated and correlated well with endoscopic 
disease activity.
ClinicalTrials. gov ID: NCT03481751











Crohn’s disease [CD] has a relapsing–remitting course which ne-
cessitates frequent follow-up examinations to monitor disease 
activity.1 Disease management was previously guided by patient-
reported symptoms, and treatment targets were based on symptom 
control. However, the patient’s symptoms do not necessarily 
correspond to inflammatory activity,2,3 and current guidelines 
recommend that management should be based on objective evalu-
ations.1,4 Furthermore, by moving therapeutic goals from clinical 
remission to objective endpoints, long-term patient outcomes seem 
to improve.5
Ileocolonoscopy is considered the reference standard method 
for determining disease status in CD.1 The endoscopic scoring sys-
tems Crohn’s Disease Endoscopic Index of Severity [CDEIS]6 and 
Simple Endoscopic Score for Crohn’s Disease [SES-CD]7 are useful 
for standardizing measurements of disease activity.8 Although 
validated and reproducible, these scoring systems are complex 
and cumbersome to use in clinical practice,9 and even though 
ileocolonoscopy is an excellent tool for activity monitoring, it 
cannot be performed on a regular basis as it is invasive, is resource-
intensive and causes considerable patient discomfort. As numerous 
follow-up examinations are required, simple non-invasive surro-
gate markers are needed.
Biomarkers such as C-reactive protein [CRP] and faecal 
calprotectin are well established in both primary work-up and dis-
ease monitoring.1 Still, as they cannot depict disease location and 
have limited accuracy,10 additional tools are required.
Cross-sectional imaging modalities such as computed tomog-
raphy [CT], magnetic resonance imaging [MRI] and ultrasound 
[US] are increasingly being used in CD management.1 As most 
of the small bowel, subepithelial structures and peri-intestinal 
complications cannot be visualized by ileocolonoscopy, these 
methods provide important contributions to the overall assess-
ment.4 In addition, they can be useful for activity monitoring, 
in which MRI and US are preferred methods, as CT causes radi-
ation exposure.1
The Magnetic Resonance Index of Activity [MaRIA]11,12 is a val-
idated MRI-based activity index that correlates well with endoscopic 
activity in CD.13 In addition, a simplified derivate of MaRIA, as well 
as other MRI-based scoring systems with comparable diagnostic 
accuracies, are currently available.14–17 As the MRI-based approach 
may reduce the need for ileocolonoscopic examinations, its import-
ance in patient management could increase significantly. Still, MRI is 
resource-intensive, requires specific preparations and has relatively 
low availability.
Gastrointestinal ultrasound [GIUS] has high diagnostic accuracy 
for detecting active CD,18 and in trained hands, it can make sig-
nificant impact on clinical decision-making.19 Furthermore, as it is 
non-invasive, readily available and can be performed bedside, the 
modality seems well suited for bedside and frequent activity moni-
toring.20 Still, interpretation of the GIUS findings may be influenced 
by the sonographer’s level of experience. A standardized ultrasound 
activity index may simplify the interpretation of the sonographic 
findings, allowing for easier comparison between different exam-
inations during follow-up. Although various sonographic activity 
scores are available,21–26 the methodology for development was 
shown to be insufficient in most studies,27 and no index is in wide-
spread clinical use. In this study, we aimed to develop, validate and 
assess inter-rater variability of a simple sonographic activity score 
for CD patients.
2.  Materials and Methods
Study design 
The study was separated into three phases, development, 
interobserver and validation, as similarly done by Daperno et  al.7 
In the development phase, we conducted a prospective single-centre 
study to identify and select the ultrasound variables that should be 
included in the activity index. In the second part, still images and 
cine loops from the included patients were re-examined to evaluate 
interobserver reliability. Finally, a scoring system consisting of sig-
nificant variables with low interobserver variability was validated in 
a prospective multicentre study.
Patients 
Forty CD patients scheduled for ileocolonoscopy as part of regular 
follow-up, including suspicion of active disease, remission, evalu-
ation of treatment effect and relapse, were prospectively recruited 
for the development phase. Patient enrolment was performed at 
the Department of Medicine at Haukeland University Hospital in 
Bergen [Norway] from 2015 to 2017. In the validation phase, a 
new population of 124 patients with identical inclusion criteria 
was prospectively recruited at the Department of Medicine at 
Haukeland University Hospital and Ålesund Hospital from 2018 
to 2019. Included patients were examined with ultrasonography, 
as well as clinical scoring and blood and stool sampling. Exclusion 
criteria were age less than 18  years, pregnancy, previous colec-
tomy, isolated disease in the upper gastrointestinal tract or ongoing 
gastroenteritis.
Clinical and biochemical tests 
Clinical assessment on the duration of CD, current medical and 
previous surgical treatment, age, sex, weight and height were 
obtained from the patients and/or access to medical records with 
consent, and each patient was phenotypically classified according 
to the Montreal classification.28 Harvey Bradshaw Index [HBI]29 
was used to assess clinical disease activity, where clinical remission 
was defined as HBI < 5. Blood and stool samples were obtained 
within 1 week prior to or after the ultrasound examination. The 
biochemical markers haemoglobin [g/dL], leukocyte count [109/L], 
platelet count [109/L], CRP [mg/L] and albumin [g/L] were meas-
ured from blood samples, whereas calprotectin [mg/kg] was ana-
lysed from faecal samples.
Ileocolonoscopy 
Ileocolonoscopy was performed as part of routine work by 20 end-
oscopists with a range of 1–30 years of experience. Disease activity 
measurements were assessed using the SES-CD in both development 
and validation phases and were calculated by the endoscopist imme-
diately after the examination. The endoscopists were blinded to the 
results from the ultrasound examination but knew clinical data such 
as HBI, previous findings and Montreal classification. The SES-CD 
evaluates four endoscopic variables [ulcer size, ulcerated surface, 
affected surface and stenosis] in five bowel segments [rectum, left 
colon, transverse colon, right colon and the terminal ileum]. Each 
parameter yields a value of 0–3 according to its severity, and by sum-
marizing the scores, segmental and total endoscopic activity can be 
quantified.7 Endoscopic remission was defined as SES-CD 0–2, as 
previously recommended.30 In the same manner as in the develop-
ment and validation of the SES-CD,7 we also included patients who 
had undergone ileocecal resection.
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Ultrasound examination development phase 
The ultrasound examinations were performed within 14 days prior 
to or after the endoscopic procedure, but not during bowel prep-
aration or just after the ileocolonoscopy as the intestine usually 
collapses, making standardization more complicated. Furthermore, 
there were no changes in medical therapy between the examinations. 
Patients were examined after an overnight fast. All examinations 
were performed by one investigator [K.N.], who was blinded to 
the results from the ileocolonoscopy, using a Logiq E9 scanner [GE 
Healthcare], with low- [C1-6, 1–6 MHz] and high-frequency [9L, 
5.5–9 MHz] probes for overview and detailed examinations of the 
bowel wall, respectively.
The large bowel scan was performed by following its course from 
the terminal ileum and further distally to the rectum, as previously 
recommended.31 In the development phase, seven well-established 
ultrasound variables (bowel wall thickness [BWT], length of affected 
segment, colour Doppler, stratification, fatty wrapping, fistula and 
stenosis) were selected and weighted according to current know-
ledge.32 The included parameters were evaluated in five ileocolonic 
segments [rectum, left colon, transverse colon, right colon and ter-
minal ileum], each yielding a numerical value corresponding to its 
severity.
BWT measurements were performed on the anterior wall in 
longitudinal section as previously described,31 and two represen-
tative measurements were averaged. In affected bowel segments 
[BWT > 3 mm], the measurements were performed in the thickest 
section, while representative measurements were performed within 
healthy bowel segments without further standardization. The rectum 
was examined using a curvilinear probe because the bowel-segment 
is deeply located, and as the rectal wall is thicker on ultrasound,33 a 
cut-off of 4 mm was used. Further classification of BWT was based 
on the authors’ clinical experience as well as from previous studies.34 
The length of the affected segments was measured in centimetres. 
Colour Doppler was performed on segments with BWT exceeding 
3 mm, using standardized scanning pre-sets. Colour Doppler meas-
urements were not performed in the rectum due to reduced sensitivity 
at increased depths. The velocity scale was set to 5 cm/s, enabling 
registration of vessels with low velocities. Gain was turned up to a 
level where flash artefacts occurred, and then lowered until they dis-
appeared. All Doppler acquisitions were performed during patient 
breath-hold. Evaluation of colour Doppler was performed using a 
modified version of that of Spalinger et al.35 [Table 1], counting the 
number of Doppler signals per cm2. Focal or diffuse loss of bowel 
wall stratification were defined as a limited hypoechoic disruption 
or total loss of bowel wall stratification, respectively. Fatty wrap-
ping was defined as a hyperechoic mass encircling the affected bowel 
loop, and stenosis as an intestinal section with total wall thickness 
greater than 3 mm, a narrow or closed off lumen, stiff appearance, 
and a lack of peristaltic movement with or without pre-stenotic dila-
tation [defined as > 2.5 mm]. Fistulas were defined as hypoechoic 
narrow tracts between the bowel loop and other tissues. The ultra-
sound variables with their corresponding definitions and score char-
acteristics are presented in Table 1 [see also Supplementary Figure 1].
Inter-rater reliability 
Before including the validation cohort, the ultrasound data from 
the development phase was reviewed by another examiner [F.S.] for 
assessing inter-rater reliability of the selected sonographic param-
eters. By using dedicated software (Phillips DICOM Viewer [Phillips 
Medical Systems] and Onis [DigitalCore, Co. Ltd]), each patient was 
re-evaluated and scored according to the activity index.
Validation phase 
GIUS was performed identically as in the development phase, using 
a Logiq E9 scanner with equal probes at both centres [Haukeland 
University Hospital and Ålesund Hospital]. The ultrasound exam-
inations were performed by two investigators [F.S. and R.E.], and 
interobserver assessments [F.S.  and K.N.] were performed in a 
subgroup of patients. All investigators were blinded to the results 
from the corresponding endoscopic examinations. Each patient was 
scored using a dedicated score sheet.
Statistics 
Descriptive statistics were used to analyse demographical data, and 
distribution was assessed by inspecting histograms as well as using 
the Shapiro-Wilk test.
Development phase 
To identify the ultrasound variables that could be eligible for further 
analysis, a correlation analysis [Spearman’s rank correlation] was 
performed between the SES-CD and each US variable. We also con-
ducted a multiple linear regression analysis to select the ultrasound 
variables to be included in the activity index, using the SES-CD as 
the dependent variable. Ultimately, the final activity index was cor-
related with the SES-CD using Spearman’s rank correlation. 
Inter-rater reliability 
Evaluation of inter-rater agreement were performed using weighted 
kappa [wκ] for the ultrasound variables as well as the calculated 
score. Additionally, intra-class correlation [ICC] and Bland–Altman36 
analyses were used to assess the level of agreement between the 
Table 1. Ultrasound variables that were eligible for inclusion in the ultrasonographic activity score for Crohn’s disease: the definition and 
score characteristics are presented for each variable.
Score
Variable 0 1 2 3
Bowel wall thickness (mm) <3.0  3.0–4.9, or 4.0–4.9 mm [rectum] 5.0–7.9 ≥ 8.0
Stenosis None Suspected [thickened wall with 
narrow lumen]
Suspected several per 
segment
Suspected with pre-stenotic 
dilatation [> 2.5 cm]
Length of affected segment (cm) None <5 5–10 >10
Colour Doppler score No or single vessel 2–5 vessels per cm2 >5 vessels per cm2  
Stratification Normal Focal loss Diffuse loss  
Fatty wrapping Absent Present   
Fistula Absent Present   
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investigators for the calculated score. The data were further tested 
for fixed and proportional biases between the observers using a one-
sided t-test and linear regression, respectively. 
Validation phase 
The US activity index was applied on a new patient cohort for val-
idation, by testing its correlation [Spearman’s rho] with the SES-CD. 
Weighted kappa, ICC and Bland–Altman analyses were used to as-
sess interobserver agreement. 
Statistics of the entire cohort 
The correlation between endoscopy, ultrasound, and clinical 
and biochemical variables was performed using Spearman’s rho. 
The patients were dichotomized into active and inactive groups 
Table 2. Clinical, biochemical and ultrasonographic characteristics of the 164 patients included in the study developing a simple ultrasono-
graphic activity score for Crohn’s disease in Bergen [Norway] from 2015 to 2017 [development] and Bergen and Ålesund from 2018 to 2019 
[validation]. 
Variable Development [range] Validation [range] Total population [range]
 n = 40 n = 124 n = 164
Endoscopic activity/remission 27/13 80/44 107/57
Sex, female/male 25/15 73/51 98/66
Age in years, median, range 37.5 [19, 83] 42.5 [18, 75] 41.5 [18,83]
Years of sickness, median, range 9 [0, 44] 10 [0, 40] 10 [0, 44]
Body mass index [BMI], kg/cm2, median, range 24.5 [17.9–34.6] 24.2 [17.9–35.8] 24.2 [17.9–35.8]
Age at diagnosis, years, n    
 <16 4 17 21
 17–40 29 84 113
 >40 7 23 30
Disease location, n    
 Ileal [L1] 14 63 77
 Colonic [L2] 8 19 27
 Ileocolonic [L3] 18 42 60
 Upper disease [L4] 1 8 9
Disease behaviour, n    
 Non‐stricturing, non-penetrating [B1] 11 61 72
 Stricturing [B2] 16 54 70
 Penetrating [B3] 13 9 22
 Perianal involvement 2 20 22
Previous surgery, n 21 46 67
Concomitant treatment, n    
 Aminosalicylate 5 15 20
 Azathioprine 12 37 49
 Methotrexate 3 9 12
 Prednisolone 1 8 9
 Budesonid 5 7 12
 Infliximab 8 39 47
 Adalimumab 6 11 17
 Certolizumab 0 1 1
 Vedolizumab 2 14 16
Biochemical tests, median, range    
 Haemoglobin, g/dL 14.1 [9.7, 17.5] 13.8 [9.1, 16.3] 13.9 [9.1, 17.5]
 Leukocyte count, 109/L 4.6 [2.2, 11.6] 6.4 [2.5, 15.9] 6.0 [2.2, 15.9]
 Platelet count, 109/L 276.5 [175, 498] 272.0 [118, 513] 275.0 [118, 513]
 Albumin, mg/L 45.5 [32, 52] 45.0 [34, 54] 45.0 [32, 54]
 C-reactive protein, mg/L 2.0 [0, 43] 1.0 [1, 96] 1.5 [0, 96]
 Calprotectin, mg/kg 74.0 [15, 2178] 39.8 [15, 1492] 42.0 [15, 2178]
Harvey Bradshaw Index [HBI], median, range 4 [0, 20] 2 [0, 12] 3 [0, 20]
Ultrasound variables, score > 0    
 Bowel wall thickness 30 86 116
 Colour Doppler 18 59 77
 Stratification 12 19 31
 Fatty wrapping 12 23 35
 Stenosis 10 ‒ ‒
 Length 30 ‒ ‒
 Fistula 0 ‒ ‒
Definitions of the pathological ultrasound variables: bowel wall thickness > 3 mm, colour Doppler > 1 Doppler signal per cm2, stratification as loss of normal 
echotexture, fatty wrapping as present, ftenosis as thickened bowel wall [>3 mm] with narrowed lumen, length as present [any length of a pathological bowel wall 
segment], fistula as present.
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at ileocolonoscopy, and receiver operating characteristics [ROC] 
curve analysis was performed to identify suitable cut-offs, as well 
as for calculation of diagnostic accuracy in terms of sensitivity 
and specificity.
Data analysis was performed using SPSS Statistics software ver-
sion 25. The level of significance was p ≤ 0.05.
Ethical consideration 
The study was approved by the Regional Ethical Committee in 
Western Norway, and each patient signed informed consent before 




Forty and 124 patients were included in the development and val-
idation cohorts, respectively. In the development cohort, 17 and 
27 patients were in clinical and endoscopic activity, respectively. 
Corresponding numbers for the validation cohort were 29 and 80 
patients. Further patient characteristics are presented in Table 2.
Development of activity index 
We found no fistulas in the development cohort and this variable 
was excluded. The remaining six ultrasound variables [BWT, colour 
Table 4. Interobserver agreement between the investigators for calculating the activity index [wκ and ICC] as well as for each included 
variable [wκ] within the two cohorts [n = 40, and n = 124, respectively].
Weighted kappa Intraclass correlation
Variable Development cohorta Validation cohortb Development cohorta Validation cohortb
 wκ, 95% CI wκ, 95% CI ICC, 95% CI ICC, 95% CI
Activity index 0.82 [0.73, 0.91] 0.84 [0.69, 0.99] 0.95 [0.90, 0.97] 0.90 [0.78, 0.96] 
BWT 0.81 [0.69, 0.93] 0.84 [0.70, 0.98]  ‒  ‒ 
Colour Doppler 0.93 [0.83, 1.00] 0.86 [0.66, 1.00]  ‒  ‒ 
Stratification 0.46 [0.24, 0.68] ‒  ‒ ‒
Fatty wrapping 0.51 [0.22, 0.81] ‒  ‒ ‒
Abbreviation: BWT, bowel wall thickness
aRe-evaluation of the development cohort using dedicated software. 
bUltrasound examination performed independently by two investigators
Table 5. Scoring sheet for the Simple Ultrasound Score for Crohn’s Disease [SUS-CD].
Variable Ileum Right colon Transverse colon Left colon Rectum Total
Bowel wall thickness [0–3]       
Colour Doppler score [0–2]       
     Score  
The severity of each variable in each segment is noted and further summed. The sum of the scores reflects the degree of disease activity. Ultrasound variables 
with their corresponding definitions and score characteristics are presented in Table 2. Colour Doppler measurements were not performed in the rectum due to 
reduced sensitivity at increased depths.
Table 3. Contributions of the different ultrasound variables eligible for inclusion in the ultrasonographic activity score for Crohn’s disease. 
The coefficient of multiple linear regression, multiple correlation [r] and Spearman correlation [rho] to SES-CD are presented based on 40 
included patients in the development part of the study.
Variable All variables Without stenosis Without fatty wrapping Without stratification Sum of all variablesa SUS-CDb
US variables       
 BWT 1.053 1.053 1.113 1.385 ‒ ‒
 Colour Doppler 1.929 1.934 2.097 2.353 ‒ ‒
 Stratification 1.223 1.225 1.389 ‒ ‒ ‒
 Fatty wrapping 1.267 1.275 ‒ ‒ ‒ ‒
 Stenosis 0.013 ‒ ‒ ‒ ‒ ‒
Intercept 0.242 0.242 0.305 0.357   
Multiple r 0.777 0.777 0.770 0.736 ‒ ‒
Rho       
 SES-CD 0.892 0.885 0.872 0.829 0.881 0.832
Abbreviations: US, ultrasound; BWT, bowel wall thickness; SUS-CD, Simple Ultrasound Score for Crohn’s Disease; SES-CD, Simple Endoscopic Score for 
Crohn’s Disease.
aSimple sum of bowel wall thickness, colour Doppler, stratification and fatty wrapping without including the regression equation.
bSimple sum of bowel wall thickness and colour Doppler.
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Doppler, stratification, fatty wrapping, length and stenosis] correl-
ated with SES-CD and were included for further analyses using mul-
tiple linear regression. All variables were tested for multicollinearity, 
revealing a high intercorrelation [r = 0.90] between BWT and length 
as well as high variance inflation factors [BWT: 5.5, length: 5.7] and 
low tolerance values [BWT: 1.8, length: 1.7] of the aforementioned 
variables. Consequently, length was excluded to ensure the assump-
tion of multicollinearity. The combination of the remaining five vari-
ables provided the highest multiple correlation coefficient [r = 0.78], 
explaining 60.4% of the variance of SES-CD. However, it was not re-
duced after exclusion of stenosis [r = 0.78]. Stenosis had only a min-
imal contribution [0.2%, p = 0.987] to the calculated model and was 
thus excluded from the final index. Only BWT [38.4%, p = 0.004] 
and colour Doppler [34.7%, p = 0.006] had significant contributions 
to the model, while less unique contributions were found for fatty 
wrapping [12.3%, p = 0.329] and stratification [22.6%, p = 0.081].
An equation for activity estimation could be derived from the multiple 
linear regression analysis: [BWT ∙ 1.053] + [Colour Doppler ∙ 1.934] + 
[Fatty wrapping ∙ 1.275] + [Stratification ∙ 1.225] + 0.242. However, 
the equation did not yield a better correlation with SES-CD than by 
summarizing the numerical values of the variables [rho = 0.885 vs 
rho = 0.881, respectively] [Table 3]. Accordingly, the sum of the four 
included ultrasonographic variables constituted the index in order to 
simplify the calculation.
The ultrasound score correlated well with SES-CD [rho = 0.88, 
p < 0.001], as well as with HBI [rho = 0.41, p = 0.009], CRP 
[rho = 0.62, p < 0.001] and calprotectin [rho = 0.51, p = 0.004].
Inter-rater reliability 
By re-scoring the development cohort, the ultrasound activity index 
correlated well with SES-CD [rho = 0.85, p < 0.001]. We also found 
good agreement between the investigators for calculating the activity 
index, as well as for BWT and colour Doppler. There was, however, 
poorer agreement for stratification and fatty wrapping [Table 4].
Stratification and fatty wrapping did not contribute significantly 
to the model, and as we revealed poor interobserver agreement, we 
further simplified the activity index by excluding these variables. 
Thus, the final ultrasound activity score, the Simple Ultrasound 
Score for Crohn’s Disease [SUS-CD], was constituted by BWT and 
colour Doppler [Table 5 and Figure 1]. The SUS-CD correlated well 
with SES-CD [rho = 0.83, p < 0.001], which was only slightly poorer 
than by using all four variables [rho = 0.88, p < 0.001]. Furthermore, 
we found excellent interobserver agreement for calculating the 
simplified score [wκ = 0.82, ICC = 0.95], and the Bland–Altman 
analysis revealed no fixed or proportional biases between the two 
investigators [Figure 2].
Validation phase 
The SUS-CD correlated well with SES-CD [rho = 0.78, p < 0.001] 
when applied on a new patient population. Corresponding values 
between the ultrasound score and HBI, CRP and calprotectin 
were 0.24, 0.42 and 0.43, respectively. A subgroup of 23 patients 
was examined by two investigators for interobserver analysis, re-
vealing excellent agreement [Table 4], and no fixed or proportional 
biases between the sonographers were found using Bland–Altman 
analysis.
Score characteristics of the entire cohort 
The SUS-CD correlated well with SES-CD [rho = 0.80, p < 0.001] 
[Figure 3]. Poorer correlations were revealed for HBI [rho = 0.33, 
p < 0.001], CRP [rho = 0.46, p < 0.001] and calprotectin [rho = 0.51, 
p < 0.001]. Similar findings were found between SES-CD and clin-
ical and biochemical markers [HBI: rho = 0.37, p < 0.001, CRP: 
rho = 0.44, p < 0.001, calprotectin: rho = 0.54, p < 0.001].
ROC curve analysis revealed an area under the curve of 0.92 
for detecting endoscopic activity [SES-CD > 2] [Figure 4], where a 
cut-off of SUS-CD ≥ 1 yielded a sensitivity of 95.3% and specificity 
of 70.3%. Thus, remission could be defined as SES-CD = 0. The cor-






Figure 1. Examples of ultrasound variables included in the activity index. 
[A] Increased bowel wall thickness with normal stratification are demarcated 
between the yellow callipers. [B] Increased colour Doppler signals 
corresponding to a score of 2. Evaluation of colour Doppler was performed 
by counting the number of Doppler signals per cm2 [within the demarcated 
























Figure 2. Bland–Altman plot displaying the agreement between the 
investigators [F.S. and K.N.] for the calculated activity index on 40 subjects. 
The size of the circles is proportional to the number of observations at the 
specific locations. The width of the agreement interval was within clinical 
acceptable limits. Interobserver analysis was performed after re-examining 
the development cohort.
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an area under the curve of 0.88, where a cut-off of SUS-CD  ≥ 3 had 
a sensitivity and specificity of 88.5% and 69.0%, respectively.
4.  Discussion
Ultrasonography is often used for follow-up examinations in pa-
tients with CD, as it is readily available, non-invasive, relatively 
inexpensive and offers high repeatability. Although focused bowel 
sonography may improve the clinical evaluation significantly,19 its 
usefulness in follow-up examinations has not been fully established, 
which may be due to operator dependency or lack of validated, re-
producible scoring systems. In this study, we developed and valid-
ated a simple ultrasound activity index for measuring disease activity 
in CD. The ultrasound score correlates well with ileocolonoscopy in 
both patient cohorts, suggesting that it is a useful surrogate marker 
of endoscopic activity. Moreover, the activity index seems reprodu-
cible as low interobserver variability was revealed, and because we 
included a heterogeneous CD population, it seems applicable at dif-
ferent disease stages.
A standardized activity index may contribute to the initial assess-
ment in CD; still, its optimal use is to monitor the same patient over 
time to determine whether the activity is decreasing or increasing. 
Although several attempts have been made to construct an ultrasono-
graphic activity index for CD, the methodology for development was 
insufficient in most studies.27 The current best method was developed 
and validated by Novak et al.26 However, in the development phase, 
no endoscopic score was used, seven ulcerative colitis patients were 
included and it was conducted retrospectively. Moreover, in the val-
idation phase, two endoscopic scoring systems were used, the cut-off 
for SES-CD was liberal [SES-CD > 5], and the ultrasonographer was 
not blinded to the results from the corresponding ileocolonoscopy. 
In our study, we sought to identify and overcome the limitations 
of previous scoring systems. The methodology for construction and 
validation of the SUS-CD was performed similarly as for the devel-
opment of the SES-CD,7 as previously suggested.27
MRI is commonly preferred in initial diagnosis as it is well suited 
for mapping extent and enables a better depiction of proximal and 
pelvic lesions than US.37 Previous reports demonstrate its ability for 
grading disease activity38 and several activity indices are available.39 
Still, due to low availability, it cannot be performed frequently. 
Furthermore, in most MRI protocols, gadolinium-based contrast 
agents are required, which may deposit in brain tissues.40 Although 
there are no currently proven harmful effects, it should be treated 
with caution and avoided when not necessary.40 Thus, an MRI-based 
approach may be less applicable for frequent activity monitoring. 
Moreover, as a recent study found good agreement between US and 
MRI in guiding clinical decision-making,41 we suggest that GIUS 
should be used as a first-line tool during follow-up.
The components of the activity index were selected using mul-
tiple linear regression to identify significant contributing variables. 
The length of the affected segment had highest correlation with 
SES-CD and provided important predictive contributions to the 
model. Still, a substantial collinearity between length of the affected 
segment and BWT was found, and thus they cancelled each other 
out. We selected BWT to be incorporated in the activity score as it 
is considered the most important sonographic variable in CD and 
is considerably easier to measure than length. Stenosis had a min-
imal unique contribution to the model and was removed from the 
final score. On ultrasonography, it is detected as a segmental bowel 
wall thickening with a narrowed lumen and pre-stenotic dilatation. 
Increased BWT, as seen in active CD, could thus cancel out stenosis, 
which may explain its poor contribution to the model. Loss of bowel 
wall stratification and fatty wrapping had higher, but not significant, 
unique contributions to the model. They were included in the assess-
ment of inter-rater reliability, but due to poor reliability they were 
excluded from the final score.
Re-examination of the development cohort showed good agree-
ment between the investigators for BWT and colour Doppler. There 
was, however, poorer agreement for stratification and fatty wrap-
ping. BWT and colour Doppler are quantifiable measurements, 
which could explain why these parameters were the easiest to re-
produce. In contrast, stratification and fatty wrapping are more 
subjective quantities, which seems to affect reproducibility. These 
results are in concordance with previous reports.42,43 In both patient 
cohorts, the interobserver analyses revealed good agreement for cal-
culating the activity index.
A clinically applicable activity score should be accurate, reprodu-
cible and easy to use. Although the ultrasound score had a slightly 
higher correlation with SES-CD when including all variables, strati-


















Figure 3. Correlation between endoscopy [SES-CD] and ultrasound score [SUS-CD] for the entire cohort. The regression line for SES-CD is depicted as 
0.731 + 1.517*SUS-CD, as well as Pearson’s [r] and Spearman’s rank correlations [rho].
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and were thus excluded from the final index. Accordingly, the final 
score is constituted by BWT and colour Doppler as they contrib-
uted significantly to the calculated model, correlated well with 
ileocolonoscopy and revealed excellent reproducibility. These re-
sults correspond to those of Novak et al.,26 although differences in 
design and methodology exist. By excluding complications, length, 
stratification and fatty wrapping, the ultrasound score does not in-
clude some important features of CD. However, the trade-off yields 
a reliable, reproducible and easy-to-use tool during follow up. The 
excluded parameters may instead serve as additional modifiers when 
present.
CD patients are regularly monitored to identify changes in dis-
ease activity, and at outpatient clinics, decision-making is usually 
limited to clinical assessment accompanied by biochemical tests. We 
found poor correlations between both the endoscopic and the ultra-
sonographic scores and clinical and biochemical markers, suggesting 
that the latter tests do not sufficiently reflect the degree of activity. 
The accuracy of clinical and biochemical activity reflected by HBI 
and CRP is limited, as previously demonstrated.2,44,45 Still, faecal 
calprotectin offers good diagnostic accuracy for detecting endoscop-
ically active CD, although higher accuracies are achieved in ulcera-
tive colitis.10,44 In our study, the patient compliance for delivering 
faecal samples was poor [40% missing data], and the majority of 
patients had only terminal ileitis, which could explain the disparities 
from previous reports.
Overall, there was a good correlation between SES-CD and 
SUS-CD, suggesting that the activity index may be a useful supple-
ment to endoscopy during follow-up. Still, the ultrasound score has 
some limitations: it has not been developed for evaluating proximal 
small bowel lesions as these exceed the reach of ileocolonoscopy. 
Moreover, the ultrasound score may not be applicable in all patients 
with a generous body habitus due to reduced visibility and Doppler 
sensitivity.31 Vendor-specific differences in Doppler quality may po-
tentially restrict widespread use of the ultrasound score. Still, this 
is a general limitation of the Doppler technique and is not limited 
to the SUS-CD score. Furthermore, mismatches between the modal-
ities may occur as GIUS does not seem sensitive enough to detect 
aphthous lesions, and BWT could increase due to chronic changes 
after surgical resection. Missing segments due to surgical resections 
are not included in the score, which could give the patient a lower 
value. Finally, as increased BWT also occurs in fibrosis, the SUS-CD 
may erroneously classify fibrotic segments as inflamed lesions, put-
ting patients at risk of receiving incorrect treatment. Thus, additional 
diagnostic methods may be necessary in the case of inappropriate 
treatment effects.
The study has some limitations. As ileocolonoscopy was per-
formed as part of standard care, the examinations were conducted 
by several endoscopists, and no formal consensus regarding SES-CD 
calculation was performed. This may lead to differences in endo-
scopic assessments. Further, re-examination of the development 
cohort was performed on identical images and video loops, which 
may contribute to good results. Still, the interobserver analysis in 
the validation phase performed by two independent investigators re-
vealed similar results. The present study comprises the development 
and validation of an ultrasound activity index using different patient 
cohorts. The scoring system should be validated by other groups 
and tested for responsiveness to changes in disease activity in future 
studies. Moreover, the SUS-CD should be compared with an MRI-
based activity index, and it should be included in follow-up studies 
to determine its usefulness in clinical decision-making.
In conclusion, we have constructed and validated a simple ultra-
sound score for CD that correlates well with endoscopic activity. 
Implementation of the activity index may aid the monitoring and 
management of CD patients and could potentially reduce the need 
for endoscopic examinations.
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Figure 4. [A] ROC curve demonstration of the ability of SUS-CD to predict 
endoscopic activity defined as SES-CD > 2. By using a cut-off of SUS-CD ≥ 1, 
a sensitivity of 95.3%, a specificity of 70.2% and an area under the curve of 
0.92 are achieved. [B] ROC curve demonstration of the ability of SUS-CD to 
predict moderate endoscopic activity defined as SES-CD ≥ 7. By using a cut-
off of SUS-CD ≥ 3, a sensitivity of 88.5%, a specificity of 69.0% and an area 
under the curve of 0.88 are achieved.
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